Skip to main content

Table 2 Characteristics of SARS-CoV-2-positive patients treated with monoclonal antibodies by vaccine status prior to treatment

From: Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study

 

Non-vaccinated n (%) n = 162

Vaccinated n (%) n = 88

p-value

Age, median (IQR)

39 (29–47)

52 (41–63)

 < 0.0001

Sex

  

0.65

 Male

73 (45)

37 (42)

 

 Female

89 (55)

51 (58)

 

Race/ethnicity

  

0.0002

 Hispanic

68 (42)

33 (38)

 

 Non-Hispanic Black

69 (43)

20 (23)

 

 Non-Hispanic White

11 (7)

20 (23)

 

 Asian

0 (0)

1 (1)

 

 Other

6 (4)

5 (6)

 

 Unavailable

8 (5)

9 (10)

 

 BMI

30 (25–35)

30 (26–35)

0.87

High-risk co-morbidities per EUA*

   

 BMI ≥ 25 kg/m2

115 (71)

67 (76)

0.66

 Pregnancy

7 (4)

0 (0)

0.054

 Chronic lung disease

33 (20)

18 (20)

0.99

 Chronic kidney disease

1 (1)

5 (6)

0.0045

 Diabetes mellitus

22 (14)

25 (28)

0.004

 Immunocompromised conditions**

12 (7)

13 (15)

0.06

 Medical-related technological dependence

1 (1)

2 (2)

0.25

 Neurodevelopmental disorders

5 (3)

0 (0)

0.17

 Cardiovascular disease or hypertension

28 (17)

36 (41)

 < 0.0001

 Number of EUA criteria met

1 (1–2)

2 (1–3)

 < 0.0001

Symptom Duration Prior to Treatment

   

 Days, median (IQR)

4 (3–6)

3 (2–5)

0.02

 Asymptomatic, n (%)

0

0

 

 Exact days unavailable, n (%)

0

1 (1)

 

Cycle threshold (Ct) values

n = 104

n = 36

0.06

 < 25

70 (67)

25 (69)

 

 Between 25 and 35

30 (29)

6 (17)

 

 > 35

4 (4)

5 (14)

 

Days between vaccination and treatment, median (IQR)

   

 Admitted (all-cause 30-day admission)

154 (118–166)

 

 Not admitted

160 (133–190)

 

Hospitalization

n = 11

n = 4

 

Outcomes

   

 All-cause 30-day admission

11 (7)

4 (5)

0.48

 COVID-19-related 30-day admission

7 (4)

1 (1)

0.27

Presenting symptoms at admission

   

 Shortness of breath

7 (64)

1 (25)

 

 Cough

3 (27)

1 (25)

 

 Fatigue

4 (36)

0

 

 Chest X-ray upon admission

9 (82)

3 (75)

 

 Requiring supplemental oxygen

3 (27)

0

 

 Asymptomatic

4 (36)

3 (75)

 

 Mild illness

1 (9)

0

 

 Moderate illness

6 (55)

1 (25)

 

 Severe or critically illness

0

0

 

Lab values on admission (where performed)

   

 White blood cell (K/uL), median (IQR)

7.5 (6–8.9)

8.7 (6–12.6)

 

 C-reactive protein†† (mg/dL), median (IQR)

4.5 (3.2–9.3)

11.8 (9.5–14.2)

 

 D-dimer§ (ug/mL), median (IQR)

0.56 (0.42–1.2)

0.66

 

 Fibrinogen§§ (ug/mL), median (IQR)

456 (384.8–591.8)

585

 

 Lactic dehydrogenase (U/L), median (IQR)

284 (232.3–344.8)

202.5 (198.3–206.8)

 
  1. *EUA: emergency use authorization
  2. **Immunocompromised conditions: HIV, cirrhosis of the liver, sickle cell anemia, asplenia, malignancy, solid organ transplant, bone marrow transplant, patient received chemotherapy, chronic steroids, tacrolimus, mycophenolate, biologics, etc.
  3. 15 patients had white blood cell test values available
  4. ††8 patients had C-reactive protein value available
  5. §8 patients had D-dimer value available
  6. §§7 patients had fibrinogen value available
  7. 10 patients had lactic dehydrogenase value available
  8. 30-day